MSH2 is a protein that helps cells fix DNA mistakes. It is one of four mismatch repair proteins that pathologists test for in many cancers. When a tumor has lost MSH2, it cannot repair these mistakes properly. Loss of MSH2 can point to an inherited condition called Lynch syndrome. It can also mean the cancer is more likely to respond to immunotherapy.
This article explains what MSH2 does, how pathologists test for it, what retained and lost MSH2 results mean, and what happens after an abnormal result.
MSH2 works like a spell-checker for DNA. Every time a cell divides, it copies all of its DNA. Small copying mistakes happen. MSH2 finds these mistakes so other proteins can fix them.
MSH2 works with another protein, MSH6. Together, they spot the mistake. A second pair, MLH1 and PMS2, then helps repair it. These four proteins make up the mismatch repair system.
The MSH2 gene holds the instructions for making the MSH2 protein. MSH2 is a tumor suppressor gene. When both copies of the gene stop working, mistakes build up in the DNA. Over time, these mistakes can lead to cancer.
Pathologists test for MSH2 using immunohistochemistry. This test uses an antibody that sticks to the MSH2 protein in a thin slice of tumor tissue. Cells that contain MSH2 show brown staining in their nuclei.
Laboratories almost always test MSH2 together with MLH1, PMS2, and MSH6. Together, the four stains make up the mismatch repair, or MMR, panel. Laboratories commonly run this panel on colorectal and endometrial cancers. They also use it for many other cancers.
The pathologist compares the tumor cells with normal cells in the same slide. Normal cells, such as immune cells and the lining of blood vessels, should always stain. They act as a built-in check that the test worked.
Your report will usually describe MSH2 as retained or lost. Each laboratory may use slightly different words:
When a tumor keeps all four MMR proteins, pathologists call it mismatch repair proficient (pMMR).
MSH2 and MSH6 are usually lost together because MSH6 needs MSH2 to stay stable. When MSH2 is missing, MSH6 also breaks down. Your report may therefore say “loss of MSH2 and MSH6.” This is one of the common abnormal MMR patterns.
The reverse is not true. A tumor can lose MSH6 alone while keeping MSH2.
Loss of MSH2 in a tumor has three main causes:
Loss of MSH2 is a strong signal to look for Lynch syndrome.
Loss of MSH2 leads to two separate questions for your care team. One is about your family, and one is about treatment.
The FDA has also approved other immunotherapy drugs for specific dMMR cancers. One example is dostarlimab, which received FDA approval in 2023 for advanced dMMR endometrial cancer that has grown after platinum chemotherapy. Approvals differ between countries. Your oncologist can explain which options apply to your cancer and stage.
MSH2 testing is most common in cancers linked to Lynch syndrome. These include:
🔍 Search MyPathologyReport
Type what you see on your report — for example a diagnosis or test name